Literature DB >> 7752652

Stereoselective vascular effects of the (R)- and (S)-enantiomers of propranolol and atenolol.

K Stoschitzky1, W Lindner, W Kiowski.   

Abstract

All beta-adrenergic antagonists have an asymmetric carbon atom, and most commercially available beta-blockers consist of (R)- and (S)-enantiomers in a fixed 1:1-ratio. The drugs are believed to be contraindicated when peripheral vascular disease exists, presumably due to unopposed alpha-adrenergic vasoconstriction. However, little is known about direct vascular effects of beta-blockers or of stereoselective effects on peripheral arteries. Therefore, we investigated the effects on forearm blood flow (FBF) of brachial artery infusions of the (R)- and (S)- enantiomers of propranolol and atenolol (2, 10, and 50 micrograms/min each) and their inhibitory effects on isoprenaline (Iso)-induced vasodilatation by forearm venous occlusion plethysmography in 12 healthy subjects. Only (R)-propranolol caused an increase in FBF (+21%, p < 0.05), whereas (S)-propranolol and (R)- and (S)-atenolol had no direct effect on peripheral arteries. Vasodilatation induced by Iso was abolished by (S)-propranolol and reduced by (R)-propranolol (-56%, p < 0.05) and (S)-atenolol (-68%, p < 0.05), whereas (R)-atenolol had no effect. Our results indicate that the optically pure (R)- and (S)-enantiomers of propranolol and atenolol do not exert direct vasoconstrictive effects. Furthermore, our results confirm that predominantly (S)-enantiomers have beta-adrenoceptor blocking effects, but they also show that neither the non-beta-blocking (R)-enantiomer of propranolol nor the (S)-enantiomer of the beta 1-selective agent atenolol is completely devoid of blocking effects on vascular beta 2-adrenoceptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7752652     DOI: 10.1097/00005344-199502000-00012

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Discrimination of Stereoisomers by Their Enantioselective Interactions with Chiral Cholesterol-Containing Membranes.

Authors:  Hironori Tsuchiya; Maki Mizogami
Journal:  Molecules       Date:  2017-12-25       Impact factor: 4.411

2.  Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.

Authors:  Caroline T Seebauer; Matthew S Graus; Lan Huang; Alex McCann; Jill Wylie-Sears; Frank Fontaine; Tara Karnezis; David Zurakowski; Steven J Staffa; Frédéric Meunier; John B Mulliken; Joyce Bischoff; Mathias Francois
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 14.808

3.  R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma.

Authors:  Jeroen Overman; Frank Fontaine; Jill Wylie-Sears; Mehdi Moustaqil; Lan Huang; Marie Meurer; Ivy Kim Chiang; Emmanuelle Lesieur; Jatin Patel; Johannes Zuegg; Eddy Pasquier; Emma Sierecki; Yann Gambin; Mohamed Hamdan; Kiarash Khosrotehrani; Gregor Andelfinger; Joyce Bischoff; Mathias Francois
Journal:  Elife       Date:  2019-07-30       Impact factor: 8.140

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.